|
Market Closed -
Nasdaq
16:00:00 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 22.50 USD | +0.27% |
|
-3.37% | - |
| 09-02 | MiniMed Type 2 Diabetes Patient Retention Holding Steady, UBS Says | MT |
| 09-02 | UBS Raises Price Target on MiniMed to $28 From $25, Keeps Buy Rating | MT |
| Market Cap | 6.32B 5.45B 5.16B 4.67B 8.77B 604B 8.81B 61.26B 23.56B 307B 23.74B 23.22B 971B | P/E 2027 * |
35.2x | P/E 2028 * | 30.3x |
|---|---|---|---|---|---|
| Enterprise Value | 6.02B 5.19B 4.92B 4.46B 8.36B 576B 8.4B 58.38B 22.45B 293B 22.63B 22.13B 925B | EV / Sales 2027 * |
1.75x | EV / Sales 2028 * | 1.54x |
| Free-Float |
10.08% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MMED | Delayed | |
CBOE
| MMED | Real-time | |
|
Deutsche Boerse AG
| B8S | Delayed | |
|
Boerse Muenchen
| B8S | Real-time | |
|
Tradegate
| B8S | Real-time | |
|
Börse Stuttgart
| B8S | Delayed |
Last Transcript : MiniMed Group, Inc.
| 1 day | +0.27% | ||
| 1 week | -3.37% | ||
| Current month | +11.06% | ||
| 1 month | +13.75% | ||
| 3 months | +45.44% | ||
| 6 months | +24.65% |
| 1 week | 22.1 |  | 23.74 |
| 1 month | 18.85 | | 24.43 |
| Current year | 10.65 | | 24.43 |
| 1 year | 10.65 | | 24.43 |
| 3 years | 10.65 | | 24.43 |
| 5 years | 10.65 | | 24.43 |
| 10 years | 10.65 | | 24.43 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/31/26 | Tax | Chief Executive Officer | -31,350 | 0.0112% | ||
| 7/31/26 | Tax | Chief Technology Officer | -8,012 | 0.0029% | ||
| 7/31/26 | Tax | General Counsel | -1,762 | 0.0006% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.27% | -3.37% | - | - | 6.31B | |
| -0.02% | -1.38% | +14.95% | +5.90% | 12.52B | |
| -0.59% | -3.06% | +10.31% | +23.79% | 6.65B | |
| -1.39% | -9.40% | +19.63% | +6.09% | 5.57B | |
| +1.23% | -3.40% | -21.54% | +39.51% | 4.98B | |
| -0.24% | -1.71% | -35.94% | -25.13% | 3.77B | |
| -1.45% | +4.81% | -7.29% | +137.35% | 1.82B | |
| +1.04% | -13.55% | +21.84% | -24.30% | 1.79B | |
| -1.07% | -5.47% | +41.34% | -20.27% | 1.59B | |
| -5.68% | -3.37% | -9.08% | +27.47% | 1.41B | |
| Average | -0.79% | -2.94% | +3.80% | +18.93% | 4.64B | |
| Weighted average by Cap. | -0.33% | -3.02% | +5.01% | +14.48% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 3.44B 2.96B 2.8B 2.54B 4.77B 328B 4.79B 33.3B 12.81B 167B 12.91B 12.62B 528B | 3.72B 3.21B 3.04B 2.75B 5.16B 355B 5.19B 36.05B 13.86B 181B 13.97B 13.67B 571B |
| Net income | 181M 156M 147M 134M 251M 17.27B 252M 1.75B 674M 8.79B 679M 664M 27.77B | 239M 206M 195M 177M 332M 22.83B 333M 2.32B 890M 11.62B 898M 878M 36.7B |
| Net Debt | -297M -256M -242M -220M -412M -28.38B -414M -2.88B -1.11B -14.44B -1.12B -1.09B -45.62B | -600M -517M -490M -444M -833M -57.34B -837M -5.82B -2.24B -29.17B -2.25B -2.2B -92.18B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | US$22.50 | +0.27% | 1,423,591 |
| 26-09-10 | US$22.44 | -1.41% | 1,652,540 |
| 26-09-09 | US$22.76 | -2.40% | 1,587,725 |
| 26-09-08 | US$23.32 | +0.15% | 1,052,149 |
| 26-09-04 | US$23.29 | -2.33% | 1,719,503 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MMED Stock
Select your edition
All financial news and data tailored to specific country editions
